MultiCare Health System

HomeBill PayMyChartAbout UsJobsWays to HelpFor ProvidersFor Staff

• Institute for Research & Innovation
  • About Us
  • Research
    • Clinical Trials
      • Cardiology
      • Cardiothoracic Surgery
      • Endocrinology
      • Gastroenterology
      • Genetics/Genomics
      • Inpatient Medicine
      • Internal Medicine
      • Neurology
      • Pulmonary Research
      • Surgery
      • Women's Health
       
    • Federal Research
    • Policies & Procedures
    • Sponsors & Collaborators
     
  • Participate in a Study
  • Become an Investigator
  • Information for Sponsors
  • Donate
   
 

Multiple Sclerosis - Relapse (Ages 18-85)

TItle: A Phase 1B, Randomized, Placebo Controlled, Multiple Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Multiple Sclerosis

Purpose: Primary objective is to evaluate the safety and tolerability of Human Placenta-Derived Cells administered IV to patients with relapsing remitting MS or secondary Progressive MS. Infusion of placental derived stem cells (from full-term live births, donated by parents) occurs on two occasions, 1 week apart and then the patient is follow closely for 2 years. Patients do no need to stop current disease modifying treatment.

Who Can Participate?

Diagnosis or Condition: Patients with relapsing remitting or secondary progressive Multiple Sclerosis with relapse in last year

Age: 18 to 85 years old

Able to walk with at least canes or walker (EDSS of 6.5 or less)

Progression or continued relapses or worsening of MRI after at least 1 year of attempted therapy

No changed in disease modifying therapy for 3 months prior to dosing

Sex: Males and Females

Visits: 7 visits over a period of 13 weeks.

Stipend: You will be compensated for your time and travel

Principal Investigator: John R. Huddleston, MD, FAAN

Study Coordinator: Sandra Reilley, MD, CPI, 253.403.7440

For more information, contact the Study Coordinator and reference Celgene Trial.